VERU
Veru Inc

19,235
Loading...
Loading...
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
210

Frequently Asked Questions

What is Market Cap of Veru Inc?
What is the 52-week high for Veru Inc?
What is the 52-week low for Veru Inc?
What is Veru Inc stock price today?
What was Veru Inc stock price yesterday?
What is the PE ratio of Veru Inc?
What is the Price-to-Book ratio of Veru Inc?
What is the 50-day moving average of Veru Inc?
How many employess does Veru Inc has?

Latest VERU News

View

Advertisement|Remove ads.

Advertisement|Remove ads.